Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...

This article introduces practical methods for evaluating AI agents operating in real-world environments. It explains how to ...